Brian Park, PharmD

Drug Information Specialist https://www.rheumatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Rheumatology

Novel Therapy for Prosthetic Joint Infections Gets Orphan Drug Status

Brian Park, PharmD

January 22, 2020

The FDA has granted Orphan Drug designation to TNP-2092 (TenNor Therapeutics) powder for intravenous IV injection for the treatment of prosthetic joint infections.

Osteoarthritis

Updated Guidelines for the Management of Osteoarthritis Released

Brian Park, PharmD

January 13, 2020

In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.

Systemic Lupus Erythematosus

Belimumab Associated With Meaningful Improvement in Lupus Nephritis Trial

Brian Park, PharmD

January 2, 2020

GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.

Rheumatoid Arthritis

Filgotinib NDA for Rheumatoid Arthritis Submitted for Priority Review

Brian Park, PharmD

December 30, 2019

Gilead Sciences has submitted a New Drug Application to the FDA for priority review of filgotinib for the treatment of moderate to severe rheumatoid arthritis in adult patients.

Rheumatoid Arthritis

Infliximab Biosimilar Gets FDA Approval

Brian Park, PharmD

December 20, 2019

The FDA has approved Avsola (infliximab-axxq; Amgen), a biosimilar to Remicade (infliximab; Janssen Biotech).

Systemic Lupus Erythematosus

Itolizumab Receives Fast Track Status for Lupus Nephritis

Brian Park, PharmD

December 18, 2019

The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.

Osteoarthritis

Sodium Hyaluronate Now Available for Osteoarthritis Knee Pain

Brian Park, PharmD

December 10, 2019

Fidia Pharma USA has announced the launch of Triluron (sodium hyaluronate), a hyaluronic acid (HA) based intra-articular viscosupplement.

Spondyloarthritis

Ixekizumab Superior to Adalimumab in Joint, Skin Improvement in Psoriatic Arthritis

Brian Park, PharmD

November 19, 2019

Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.

Spondyloarthritis

Improvement in Joint Symptoms, Pain With Tildrakizumab-asmn in Psoriatic Arthritis

Brian Park, PharmD

November 15, 2019

Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results.

Psoriatic Arthritis

Upadacitinib Meets Primary and Secondary End Points in Psoriatic Arthritis Trial

Brian Park, PharmD

November 4, 2019

AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).

Next post in Psoriatic Arthritis